Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,006 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, Krop IE, Gonzàlez Farré X, You B, Saura C, Kim SB, Osborne CR, Murthy RK, Gianni L, Takano T, Liu Y, Cathcart J, Lee C, Perrin C. Jerusalem G, et al. Among authors: park yh. Cancer Discov. 2022 Dec 2;12(12):2754-2762. doi: 10.1158/2159-8290.CD-22-0837. Cancer Discov. 2022. PMID: 36255231 Free PMC article.
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Park YH, Lee KH, Sohn JH, Lee KS, Jung KH, Kim JH, Lee KH, Ahn JS, Kim TY, Kim GM, Park IH, Kim SB, Kim SH, Han HS, Im YH, Ahn JH, Kim JY, Kang J, Im SA. Park YH, et al. Among authors: park ih. Int J Cancer. 2018 Dec 15;143(12):3240-3247. doi: 10.1002/ijc.31651. Epub 2018 Nov 7. Int J Cancer. 2018. PMID: 29978467 Free article. Clinical Trial.
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
Kim JY, Lee E, Park K, Jung HH, Park WY, Lee KH, Sohn J, Lee KS, Jung KH, Kim JH, Lee KH, Im SA, Park YH. Kim JY, et al. Among authors: park yh, park k, park wy. Int J Cancer. 2019 Sep 15;145(6):1669-1678. doi: 10.1002/ijc.32188. Epub 2019 Feb 27. Int J Cancer. 2019. PMID: 30720867 Free article. Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. Among authors: park yh. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: park yh. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: park yh. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Hurvitz SA, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, Prat A, Gilham L, Boulet T, Gochitashvili N, Monturus E, Lambertini C, Nyawira B, Knott A, Restuccia E, Schmid P. Hurvitz SA, et al. Among authors: park yh. Future Oncol. 2022 Oct;18(32):3563-3572. doi: 10.2217/fon-2022-0485. Epub 2022 Nov 16. Future Oncol. 2022. PMID: 36382554 Free article.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. Among authors: park yh. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Among authors: park yh, park simon tw. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
3,006 results